Table 3.
Clinical and laboratory features of the cases with PCH and TCH at the withdrawal of LT4
| Permanent CH (n = 111) | Transient CH (n = 128) | p-value | Eutopic Permanent CH (n = 63) | Eutopic Transient CH (n = 125) | p-value | |
|---|---|---|---|---|---|---|
| Serum TSH (µIU/mL)* | 3.88 (2.50–5.50) | 2.41 (1.61 -3.33) | < 0.001& | 3.5 (2.40–5.12) | 2.43 (1.6–3.3) | < .0.001& |
| Serum FT4 (ng/dl)* | 1.32 (1.16–1.47) | 1.20 (1.08 -1.38) | 0.005& | 1.31 (1.16–1.47) | 1.20 (1.09–1.38) | 0.021& |
| LT4 dose at the withdrawal of treatment (µg/kg/day)* | 2 (1.30–2.50) | 1.2 (0.9–1.5) | < 0.001& | 1.80 (1.20–2.2) | 1.20 (0.9–1.5) | < 0.001& |
| Age at the withdrawal of LT4 (months)* | 36 (35.80–37.80) | 36 (33.80–38.0) | 0.634& | 36 (35.5–39.5) | 36 (33.0–38.0) | 0.625& |
*Median (Q1-Q3)
&Mann-Whitney U test was used
TCH Transient congenital hypothyroidism, PCH Permanent congenital hypothyroidism, TSH Thyroid stimulating hormone, FT4 Free thyroxine, LT4 L-thyroxine
Serum TSH level and LT4 dose at the withdrawal of treatment were significantly higher in cases with PCH